SCHEMBL1022524

SCHEMBL1022524

CCN(CCN(CC)S(=O)(=O)c1cccs1)c1nc(Cc2ccc(C)cc2)ns1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.39
CNR1 P21554 2/20 0.39
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
PGGT1B P53609 1/20 0.35
ALDH1A1 P00352 6/20 0.35
MAPT P10636 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HTT P42858 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33
LMNA P02545 1/20 0.33
SQLE Q14534 1/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021855 0.92 FNTA (0.41) CNR2FNTAFNTBPGGT1BALDH1A1
SCHEMBL1019501 0.91 TAS2R14 (0.38) CNR2CNR1FNTAFNTBPGGT1B
SCHEMBL1019785 0.91 NPC1 (0.35) CNR2CNR1FNTAFNTBPGGT1B
SCHEMBL1020807 0.90 SQLE (0.36) CNR2CNR1FNTAFNTBPGGT1B
SCHEMBL1018654 0.90 ALDH1A1 (0.38) CNR2CNR1ALDH1A1MAPTMEN1
SCHEMBL1019792 0.87 MEN1 (0.35) CNR2CNR1FNTAFNTBPGGT1B
SCHEMBL1019782 0.86 RAB9A (0.35) FNTAFNTBPGGT1BALDH1A1MAPT
SCHEMBL1019424 0.85 SQLE (0.36) FNTAFNTBPGGT1BALDH1A1MEN1
SCHEMBL1021265 0.83 NPC1 (0.35) FNTAFNTBPGGT1BALDH1A1MAPT
SCHEMBL1021642 0.81 ALDH1A1 (0.37) FNTAFNTBPGGT1BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP CNR2 3443/4885CNR1 3094/4885FNTA 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.